Pair Name	Glucosinalbate, Doxorubicin
Disease Info	[ICD-11: 2C90]	Ehrlich ascites carcinoma		Investigative
Biological Phenomena	Inhibition-->Angiogenesis
Gene Regulation	Down-regulation	Expression	VEGFA	hsa7422
	Down-regulation	Expression	MMP9	hsa4318
	Down-regulation	Expression	BCL2	hsa596
	Up-regulation	Expression	BAX	hsa581
	Up-regulation	Cleavage	CASP3	hsa836
	Up-regulation	Cleavage	PARP1	hsa142
	Up-regulation	Expression	CYCS	hsa54205
	Up-regulation	Expression	CASP9	hsa842
	Up-regulation	Expression	APAF1	hsa317
	Down-regulation	Expression	RELA	hsa5970
	Up-regulation	Expression	LBR	hsa3930
	Up-regulation	Expression	NFKBIA	hsa4792
	Up-regulation	Expression	NFE2L2	hsa4780
	Down-regulation	Expression	KEAP1	hsa9817
	Up-regulation	Expression	NQO1	hsa1728
	Up-regulation	Expression	HMOX1	hsa3162
	Up-regulation	Expression	GSTP1	hsa2950
	Down-regulation	Expression	PTGS2	hsa5743
	Down-regulation	Expression	NOS2	hsa4843
	Down-regulation	Expression	IL6	hsa3569
In Vivo Model	Ehrlich ascites carcinoma cell was maintained in Swiss albino mice by weekly intraperitoneal transplantation of 1×10⁶ viable tumor cells suspended in isotonic phosphate-buffered solution (PBS).
Result	The present study clearly suggested therapeutic benefit of I3C in combination with DOX by augmenting anticancer efficacy and diminishing toxicity to the host.